startup.bid
FR
EnglishEspañolPortuguêsFrançaisDeutschItalianoNederlandsSvenskaDanskNorskPolskiSlovenščinaTürkçeРусскийBahasa IndonesiaBahasa MelayuFilipinoTiếng ViệtKiswahiliहिन्दीاردوالعربيةעברית日本語한국어中文繁體中文

zPREDICTA

Patient-derived 3D tissue reconstruction models for preclinical…

Rachetée

À propos

Description de l’entreprise en anglais

zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response. The ability of the zPREDICTA platform to reliably predict clinical outcomes offers superior compound attrition management, empowering researchers to exclude ineffective compounds while selecting agents with a high probability of success in the clinic.

Our approach is compatible with any drug class, multiple tissue/cell types and a wide variety of readouts. Our customers are using these models for efficacy screening of anticancer compounds, including immuno-oncology agents, evaluation of mechanisms of drug resistance, the rescue of failed drug candidates, assessment of off-target toxicity, and a multitude other applications.

Thèmes

Localisation
San Francisco, CA, États-Unis
Équipe
2 employés
Promotion YC
Summer 2015
Statut
Rachetée
Stade
Phase d’amorçage

Startups similaires et concurrents

Questions et réponses

Où se trouve zPREDICTA ?

San Francisco, CA, États-Unis

Combien de personnes travaillent chez zPREDICTA ?

2 employés, d’après le profil de l’entreprise.

L’entreprise zPREDICTA a-t-elle levé des fonds ?

Nos données ne contiennent aucune levée de fonds pour zPREDICTA.

Quelles sont les alternatives à zPREDICTA ?

Startups similaires : Numerion Labs, Verge Genomics et PostEra.